Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.
IRCCS SDN, Naples, Italy.
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1630-1639. doi: 10.1007/s00259-021-05625-4. Epub 2021 Nov 25.
Although it has been proven that radioactive iodine (RAI) treatment is an effective and well-tolerated procedure in patients with differentiated thyroid cancer (DTC), there is still some concern regarding the risk of developing a second primary malignancy after RAI administration. We performed a systematic review and meta-analysis to investigate the risk of primary breast cancer in patients with DTC undergoing RAI therapy.
A comprehensive literature search of the PubMed, Scopus, and Web of Science databases was conducted according to the PRISMA statement.
The final analysis included 14 studies accounting for a total of 200,247 patients with DTC (98,368 treated with RAI and 101,879 not treated with RAI). The relative risk of primary breast cancer in patients with DTC treated with RAI to those not treated with RAI among studies ranged from 0.45 to 2.55, the pooled relative risk was 0.83 (95% confidence interval, 0.70-0.99), and the heterogeneity was 71.5%.
The present meta-analysis indicates that patients with DTC treated with RAI do not have a higher risk of primary breast cancer compared to those not treated with RAI. These findings suggest that RAI therapy does not increase the risk of breast cancer.
尽管放射性碘（RAI）治疗已被证明是分化型甲状腺癌（DTC）患者有效且耐受性良好的治疗方法，但人们仍对 RAI 给药后发生第二原发恶性肿瘤的风险存在一些担忧。我们进行了系统评价和荟萃分析，以调查接受 RAI 治疗的 DTC 患者发生原发性乳腺癌的风险。
根据 PRISMA 声明，对 PubMed、Scopus 和 Web of Science 数据库进行了全面的文献检索。
最终分析包括 14 项研究，共纳入 200247 例 DTC 患者（98368 例接受 RAI 治疗，101879 例未接受 RAI 治疗）。在研究中，接受 RAI 治疗的 DTC 患者发生原发性乳腺癌的相对风险范围为 0.45 至 2.55，合并相对风险为 0.83（95%置信区间，0.70-0.99），异质性为 71.5%。
本荟萃分析表明，与未接受 RAI 治疗的患者相比，接受 RAI 治疗的 DTC 患者发生原发性乳腺癌的风险没有增加。这些发现表明 RAI 治疗不会增加乳腺癌的风险。
